BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 29, 2002
View Archived Issues
Dendreon Gets OK To Resume Enrollment In Phase III Study
Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. (BioWorld Today)
Read More
Peninsula Raises $22.1M To Fund In-Licensing Program
Read More
NIH Scientists Report Finding New Deafness Gene, Mucolipin By Name, Joining Worldwide Panoply Of Same
Read More
Abbott's Humira Continues To Impress In RA Treatment
Read More
Other News To Note
Read More
Correction
Read More
Endo's Second Phase III For MorphiDex Misses Endpoint
Read More
Aphton Reports Phase III Results Showing G17DT Extends Survival
Read More